Chemokine Receptor Studies: Defining the Dynamics of the Chemosynapse
Chemokine Receptor Studies: Defining the Dynamics of the Chemosynapse
批准号:
7915941
负责人:
Ann Richmond
金额:
$21.94万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-08-01 至 2011-07-31
关键词:
1-Phosphatidylinositol 3-KinaseActinsAdaptor Signaling ProteinAffectArrestinsArthritisBackBindingBiologicalBreast Cancer CellCXCR4 geneCancer cell lineCell membraneCellsChemotaxisChronicClathrinClathrin-Coated VesiclesComplexCytokinesisCytoplasmCytoskeletonDOCK1 proteinDataDevelopmentDissociationDynaminEarly EndosomeEndocytic VesicleEndosomesEndothelial CellsEventExtravasationG-Protein-Coupled ReceptorsGTP-Binding ProteinsGTPase-Activating ProteinsGuanosine TriphosphateGuanosine Triphosphate PhosphohydrolasesHeat-Shock ResponseHeterotrimeric G Protein SubunitIL8 geneIL8RB geneImageImmuneIn VitroInflammationLeukocyte ChemotaxisLeukocytesLigand BindingLigandsLinkLysosomesMCF7 cellMaintenanceMalignant NeoplasmsMediatingMembraneMicrofluidic MicrochipsModelingMonomeric GTP-Binding ProteinsNeoplasm MetastasisPathway interactionsPharmacotherapyPhosphatidylinositol 4,5-DiphosphatePhosphotransferasesPhotonsProcessProtein BindingProtein Phosphatase 2A Regulatory Subunit PR53ProteinsRecruitment ActivityRecyclingResistanceRoleSepsisSerineSignal TransductionTestingTimeTumor AngiogenesisVesiclearrestin 2cdc42 GTP-Binding Proteincell motilitychemokinechemokine receptorclathrin Acoated pithuman BCAR1 proteinin vivoinsightintravital microscopykinase inhibitorlate endosomeneoplastic cellneutrophilnew therapeutic targetnumb proteinperlecanprotein protein interactionpublic health relevancereceptorresponsesrc-Family Kinasestherapy designtraffickingtumor growthvasodilator-stimulated phosphoproteinwortmannin
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): We propose to test the hypothesis that when ligand binds chemokine receptors, a "dynamic chemosynapse" forms, comprised of receptor and adaptor proteins that serve to enable polarization, activation, amplification, and oscillation of small GTPases and kinases involved in organization of the actin cytoskeleton, and chemotaxis. Moreover, we propose that interference of chemokine receptor association with these adaptors will ablate CXCR2- and CXCR4-mediated chemotaxis, intravasation, extravasation, and metastasis. There are three specific aims. I) To test the hypothesis that a major role of AP-2 in mediating CXCR2/CXCR4 chemotaxis and metastasis is to orchestrate polarization and amplification of intracellular signals. We will separately interfere with AP-2 mediated receptor trafficking versus polarization of intracellular signals to distinguish the importance of these two functions of AP-2 in CXCR2/CXCR4 mediated chemotaxis and metastasis. 2) To characterize the role of IQGAP1 and VASP in linking the CXCR2 and CXCR4 chemosynapse to the actin cytoskeleton. We will characterize the interacting domains of IQGAP1 and VASP with CXCR2 and CXCR4 and determine the effects of altering these interactions on the functional responses to chemokine (including extravasation, intravasation, metastasis) of leukocytes, endothelial cells and breast cancer cells. 3) To test the hypothesis that Src-family kinase activation at the CXCR2 and CXCR4 `chemosynapse' drives chemotaxis that is Dock2 dependent and largely PI3K independent. We will determine the role of the Src-p130Cas-CrkL-Dock2 pathway in PI3K independent CXC2/CXCR4 chemotaxis. We will study these processes in dHL-60, dU937, HMEC-1 CXCR2 expressing cells and in the breast cancer cell lines naturally expressing CXCR4 (highly invasive MDA-MB-231, DU4475, BT-549 and non-invasive MCF-7, MDA-MB- 453 and MCF-10A cells). Microfluidic devices and real time intravital microscopy using 2 photon imaging will be used to track chemotaxis in vitro and intravasation/extravasation /metastasis in vivo, respectively. Characterization of the functional significance of this interaction between chemokine receptors and adaptor proteins that comprise the chemosynapse will unveil important new therapeutic targets for the treatment of malignancies. Characterization of the mechanism for PI3K independent chemotaxis will provide valuable information for design of therapies for sepsis, arthritis, and metastasis. PUBLIC HEALTH RELEVANCE: This study aims to test the hypothesis that receptors involved in regulating the motility of immune cells and tumor cells must interact with a number of proteins in the cytoplasm of the cell to stimulate proper organization of the cytoskeleton. In this study we propose to disrupt these protein/protein interactions to develop a new way of blocking tumor cell metastasis and chronic inflammation. We also will interrupt specific intracellular signals initiated by these protein/protein interactions to point the way to new targets for drug therapy for chronic inflammation and metastasis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
BLR&D Merit Review Research Career Scientist (RCS) Award (IK6)
-
批准号:10618231
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:Ann Richmond
-
依托单位:
BLR&D Merit Review Research Career Scientist (RCS) Award (IK6)
-
批准号:10454101
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:Ann Richmond
-
依托单位:
Optimizing Response to Immune Checkpoint Inhibitor Therapy for Breast Cancer: A Role for Inhibitors of the PI3K pathway
-
批准号:10305634
-
项目类别:
-
资助金额:$35.62万
-
财政年份:2019
-
负责人:Ann Richmond
-
依托单位:
Optimizing Response to Immune Checkpoint Inhibitor Therapy for Breast Cancer: A Role for Inhibitors of the PI3K pathway
-
批准号:9916443
-
项目类别:
-
资助金额:$37.65万
-
财政年份:2019
-
负责人:Ann Richmond
-
依托单位:
Optimizing Response to Immune Checkpoint Inhibitor Therapy for Breast Cancer: A Role for Inhibitors of the PI3K pathway
-
批准号:10531596
-
项目类别:
-
资助金额:$35.62万
-
财政年份:2019
-
负责人:Ann Richmond
-
依托单位:
Combining Immune Therapy with Targeted Therapies to Improve Melanoma Survival
-
批准号:10609814
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2013
-
负责人:Ann Richmond
-
依托单位:
Combining Immune Therapy with Targeted Therapies to Improve Melanoma Survival
-
批准号:10369756
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2013
-
负责人:Ann Richmond
-
依托单位:
Modeling New Therapeutic Approaches for Malignant Melanoma
-
批准号:8817140
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2013
-
负责人:Ann Richmond
-
依托单位:
Combining Immune Therapy with Targeted Therapies to Improve Melanoma Survival
-
批准号:10265337
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2013
-
负责人:Ann Richmond
-
依托单位:
Modeling New Therapeutic Approaches for Malignant Melanoma
-
批准号:8633274
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2013
-
负责人:Ann Richmond
-
依托单位:
Modeling New Therapeutic Approaches for Malignant Melanoma
-
批准号:8966669
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2013
-
负责人:Ann Richmond
-
依托单位:
Targeting IKK beta and aurora kinases in melanoma
-
批准号:8195848
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:Ann Richmond
-
依托单位:
Targeting IKK beta and aurora kinases in melanoma
-
批准号:7797846
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:Ann Richmond
-
依托单位:
Targeting IKK beta and aurora kinases in melanoma
-
批准号:7912888
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:Ann Richmond
-
依托单位:
Targeting IKK beta and aurora kinases in melanoma
-
批准号:8391117
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:Ann Richmond
-
依托单位:
Targeting the NF-kappaB Pathway in Melanoma
-
批准号:7115276
-
项目类别:
-
资助金额:$29.51万
-
财政年份:2005
-
负责人:Ann Richmond
-
依托单位:
Impact of IKKB and AurK Inhibitors on Host Immunity and Melanoma
-
批准号:8091397
-
项目类别:
-
资助金额:$32.84万
-
财政年份:2005
-
负责人:Ann Richmond
-
依托单位:
Targeting the NF-kappaB Pathway in Melanoma
-
批准号:7459854
-
项目类别:
-
资助金额:$28.75万
-
财政年份:2005
-
负责人:Ann Richmond
-
依托单位:
Impact of IKKB and AurK Inhibitors on Host Immunity and Melanoma
-
批准号:7992308
-
项目类别:
-
资助金额:$14.95万
-
财政年份:2005
-
负责人:Ann Richmond
-
依托单位:
Role of NIK Activation in Melanoma Progression
-
批准号:7229584
-
项目类别:
-
资助金额:$25.87万
-
财政年份:2005
-
负责人:Ann Richmond
-
依托单位:
海外基金